Doctors from around the world came together to test a medicine for type 2 diabetes. They did this test in 14 countries at 177 places. The main person in charge was Dr. Vanita R. Aroda from a hospital in Boston.
What Was The Study About?
People with type 2 diabetes have a higher level of sugar in their blood. One way to measure this is by checking a thing called HbA1c.
In this study, people who had HbA1c between 8.0 to 10.5 percent were chosen. These people also had a certain body weight. They were already taking 1 to 3 sugar-lowering pills every day.
The study gave these people a new medicine called semaglutide. They had to take it once every day. There were three different amounts of this medicine: 14 mg, 25 mg, and 50 mg.
People were split into three groups and each group took one amount for 68 weeks.
The main goal was to see if the medicine could lower the HbA1c number in one year.
What Did They Find Out?
After one year, all three doses helped lower the HbA1c number. But, the 25 mg and 50 mg doses worked better than the 14 mg dose. The bigger the dose, the more it lowered the HbA1c.
Some people had side effects like stomach problems. But these side effects were mostly mild and happened more in the 25 mg and 50 mg groups.
In Simple Words
This study showed that for people with type 2 diabetes, taking the 25 mg or 50 mg dose of semaglutide every day was better than taking the 14 mg dose.
It helped lower their blood sugar more. But, it’s important to remember that some people might have stomach problems with the higher doses.
The people in charge of the study said that the 25 mg and 50 mg doses not only helped control the blood sugar better but also helped people lose some weight.
If you care about diabetes, please read studies about new drugs to treat diabetes and metabolic syndrome, and heavy cannabis use may decrease the incidence of diabetes.
For more information about health, please see recent studies about the normal blood sugar for people with diabetes, and results showing Vitamin E may help prevent Parkinson’s disease.
The study was published in The Lancet.
Follow us on Twitter for more articles about this topic.
Copyright © 2023 Knowridge Science Report. All rights reserved.
